CVS Health Confirms Split Into Two Companies While Posting Blowout Q3 Earnings Beat

CVS Health confirmed plans to separate its roughly 9,000 retail pharmacies into a standalone publicly traded company, splitting apart from its Aetna insurance and Caremark pharmacy benefits management businesses. The transaction is expected to close in the first half of 2028 and would effectively unwind the company's $78 billion acquisition of Aetna in 2018, dismantling the vertically integrated healthcare conglomerate that deal created.

Alongside the structural announcement, CVS reported third-quarter 2026 results that significantly exceeded expectations. Adjusted EPS came in at $2.09 against an estimate of $1.65 to $1.66, a beat of $0.44, while revenue reached $108.4 billion versus the consensus of roughly $104.6 billion, a top-line beat of approximately $3.8 billion. Revenue grew 5.4% year over year and adjusted operating income was $4.19 billion against an estimate of $3.61 billion. The Health Services segment, which includes Caremark, was the standout at $53.96 billion in revenue and $2.11 billion in adjusted operating income, up 9.5% year over year. The medical benefit ratio improved 150 basis points year over year to 91.3%.

CVS raised its full-year 2026 guidance across the board. Adjusted EPS guidance was lifted to at least $8.20 from a prior range of $7.90 to $8.10, revenue guidance moved to at least $420 billion from at least $414 billion, and cash flow from operations guidance jumped to at least $15.5 billion from at least $11.5 billion. The company reported $15.3 billion in year-to-date operating cash flow through Q3. Despite the earnings beat and raised guidance, shares declined on the day, with analysts at Mizuho, Raymond James, TD Cowen, Evercore ISI, and Bank of America all reiterating their existing ratings. CEO David Joyner cited improving the consumer experience, lowering healthcare costs, and connecting care as the company's strategic priorities.